FABP5 and breast cancer: TAMs can increase the level of FABP5 and PPAR (peroxisome proliferator-activated receptors) in BC cells, activating the CaMKII (Ca2+/calmodulin-dependent protein kinase II) signaling pathway and leading to resistance to Doxorubicin (which is a commonly prescribed drug for BC) [137].